Roivant Sciences Ltd (NASDAQ:ROIV) shares, rose in value, with the stock price down by -0.88% to the previous day’s close as strong demand from buyers drove the stock to $10.14.
Actively observing the price movement in the last trading, the stock closed the session at $10.23. The value of beta (5-year monthly) was 1.37 whereas the PE ratio was 1.95 over 12-month period. Referring to stock’s 52-week performance, its high was $13.24, and the low was $6.59. On the whole, ROIV has fluctuated by -10.42% over the past month.
With the market capitalization of Roivant Sciences Ltd currently standing at about $8.17 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.3, which is expected to increase to -$0.28 for fiscal year $4.55 and then to about -$1.15 by fiscal year 2025. Data indicates that the EPS growth is expected to be 388.00% in 2025, while the next year’s EPS growth is forecast to be -125.30%.
Analysts have estimated the company’s revenue for the quarter at $33.72 million, with a low estimate of $27.5 million and a high estimate of $41 million. According to the average forecast, sales growth in current quarter could jump up 23.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $145.42 million, representing an increase of 137.30% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ROIV’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ROIV currently trading nearly -10.09% and -6.91% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.94, while the 7-day volatility ratio is showing 3.82% which for the 30-day chart, stands at 3.46%. Furthermore, Roivant Sciences Ltd (ROIV)’s beta value is 1.37, and its average true range (ATR) is 0.40.
A comparison of Roivant Sciences Ltd (ROIV) with its peers suggests the former has fared considerably weaker in the market. ROIV showed an intraday change of -0.88% in last session, and over the past year, it grew by 18.04%%.
Data on historical trading for Roivant Sciences Ltd (NASDAQ:ROIV) indicates that the trading volumes over the past 10 days have averaged 5.87 million and over the past 3 months, they’ve averaged 5.49 million. According to company’s latest data on outstanding shares, there are 760.14 million shares outstanding.
Nearly 40.16% of Roivant Sciences Ltd’s shares belong to company insiders and institutional investors own 50.51% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 27.69 million shares as on Feb 29, 2024, resulting in a short ratio of 4.61. According to the data, the short interest in Roivant Sciences Ltd (ROIV) stood at 3.44% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 25.71 million. The stock has fallen by -9.71% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ROIV stock heading into the next quarter.
